Induction of depression with oxotremorine in patients with Alzheimer's disease

K. L. Davis, Eric Hollander, M. Davidson, R. C. Mohs, T. B. Horvath

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Cholinergic neurotransmission has long been implicated in the development of depression. In this study seven patients with Alzheimer's disease were given oral oxotremorine, a long-acting cholinergic agonist, to assess the drug's effect on cognitive function. There were unexpected depressive reactions in five of the seven patients; three patients dropped out of the study because of these side effects. Cardiovascular effects of the drug were negligible, but its effect on memory and cognition remains unknown because of the small number of subjects who completed the study.

Original languageEnglish (US)
Pages (from-to)468-471
Number of pages4
JournalAmerican Journal of Psychiatry
Volume144
Issue number4
StatePublished - 1987
Externally publishedYes

Fingerprint

Oxotremorine
Alzheimer Disease
Depression
Cognition
Cardiovascular Agents
Cholinergic Agonists
Synaptic Transmission
Cholinergic Agents
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Davis, K. L., Hollander, E., Davidson, M., Mohs, R. C., & Horvath, T. B. (1987). Induction of depression with oxotremorine in patients with Alzheimer's disease. American Journal of Psychiatry, 144(4), 468-471.

Induction of depression with oxotremorine in patients with Alzheimer's disease. / Davis, K. L.; Hollander, Eric; Davidson, M.; Mohs, R. C.; Horvath, T. B.

In: American Journal of Psychiatry, Vol. 144, No. 4, 1987, p. 468-471.

Research output: Contribution to journalArticle

Davis, KL, Hollander, E, Davidson, M, Mohs, RC & Horvath, TB 1987, 'Induction of depression with oxotremorine in patients with Alzheimer's disease', American Journal of Psychiatry, vol. 144, no. 4, pp. 468-471.
Davis, K. L. ; Hollander, Eric ; Davidson, M. ; Mohs, R. C. ; Horvath, T. B. / Induction of depression with oxotremorine in patients with Alzheimer's disease. In: American Journal of Psychiatry. 1987 ; Vol. 144, No. 4. pp. 468-471.
@article{bfab74bdfb7e49019e8b891cba5b2d15,
title = "Induction of depression with oxotremorine in patients with Alzheimer's disease",
abstract = "Cholinergic neurotransmission has long been implicated in the development of depression. In this study seven patients with Alzheimer's disease were given oral oxotremorine, a long-acting cholinergic agonist, to assess the drug's effect on cognitive function. There were unexpected depressive reactions in five of the seven patients; three patients dropped out of the study because of these side effects. Cardiovascular effects of the drug were negligible, but its effect on memory and cognition remains unknown because of the small number of subjects who completed the study.",
author = "Davis, {K. L.} and Eric Hollander and M. Davidson and Mohs, {R. C.} and Horvath, {T. B.}",
year = "1987",
language = "English (US)",
volume = "144",
pages = "468--471",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "4",

}

TY - JOUR

T1 - Induction of depression with oxotremorine in patients with Alzheimer's disease

AU - Davis, K. L.

AU - Hollander, Eric

AU - Davidson, M.

AU - Mohs, R. C.

AU - Horvath, T. B.

PY - 1987

Y1 - 1987

N2 - Cholinergic neurotransmission has long been implicated in the development of depression. In this study seven patients with Alzheimer's disease were given oral oxotremorine, a long-acting cholinergic agonist, to assess the drug's effect on cognitive function. There were unexpected depressive reactions in five of the seven patients; three patients dropped out of the study because of these side effects. Cardiovascular effects of the drug were negligible, but its effect on memory and cognition remains unknown because of the small number of subjects who completed the study.

AB - Cholinergic neurotransmission has long been implicated in the development of depression. In this study seven patients with Alzheimer's disease were given oral oxotremorine, a long-acting cholinergic agonist, to assess the drug's effect on cognitive function. There were unexpected depressive reactions in five of the seven patients; three patients dropped out of the study because of these side effects. Cardiovascular effects of the drug were negligible, but its effect on memory and cognition remains unknown because of the small number of subjects who completed the study.

UR - http://www.scopus.com/inward/record.url?scp=0023177967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023177967&partnerID=8YFLogxK

M3 - Article

VL - 144

SP - 468

EP - 471

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 4

ER -